- Home
- IMNM
IMNM
Immunome Inc.
as of 02-05-2026 3:57pm EST
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BOTHELL |
| Market Cap: | 2.2B | IPO Year: | 2020 |
| Target Price: | $31.22 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.15 - $27.65 | Next Earning Date: | 03-18-2026 |
| Revenue: | $9,679,000 | Revenue Growth: | -4.44% |
| Revenue Growth (this year): | -18.43% | Revenue Growth (next year): | 11.53% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -191838000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of Immunome Inc. (IMNM)
President and CEO
Avg Cost/Share
$21.15
Shares
4,729
Total Value
$100,018.35
Owned After
665,254
SEC Form 4
Director
Avg Cost/Share
$22.03
Shares
383,200
Total Value
$8,330,079.62
Owned After
2,042,432
President and CEO
Avg Cost/Share
$20.48
Shares
7,278
Total Value
$149,053.44
Owned After
665,254
SEC Form 4
Chief Technical Officer
Avg Cost/Share
$20.49
Shares
10,000
Total Value
$204,900.00
Owned After
43,300
SEC Form 4
President and CEO
Avg Cost/Share
$21.50
Shares
46,511
Total Value
$999,986.50
Owned After
665,254
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| SIEGALL CLAY B | IMNM | President and CEO | Dec 30, 2025 | Buy | $21.15 | 4,729 | $100,018.35 | 665,254 | |
| Barchas Isaac | IMNM | Director | Dec 22, 2025 | Sell | $22.03 | 383,200 | $8,330,079.62 | 2,042,432 | |
| SIEGALL CLAY B | IMNM | President and CEO | Dec 19, 2025 | Buy | $20.48 | 7,278 | $149,053.44 | 665,254 | |
| Tsai Philip | IMNM | Chief Technical Officer | Dec 19, 2025 | Buy | $20.49 | 10,000 | $204,900.00 | 43,300 | |
| SIEGALL CLAY B | IMNM | President and CEO | Dec 18, 2025 | Buy | $21.50 | 46,511 | $999,986.50 | 665,254 |
Compare IMNM vs Leading Stocks
See how IMNM stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "IMNM Immunome Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.